Latest Report Overview for Amgen Inc ($AMGN)
AI-powered analysis of Amgen Inc (AMGN) stock based on Q1 2026 financial data.
Latest Report Overview
Amgen Inc. (AMGN) reported For the quarterly period ended March 31, 2026 (Issuer fiscal Q1 FY2026) revenue of $8,618 million (+5.8% YoY) with net income of $1,819 million and diluted EPS of $3.34. A standout performance indicator was the significant volume growth in key brands such as Repatha, IMDELLTRA, and EVENITY, despite continued downward pressure from net selling price declines and inventory adjustments across the portfolio. The results highlight the ongoing transformation of the company’s portfolio as it navigates significant patent expirations for legacy blockbusters like Prolia and XGEVA. Management continues to invest heavily in R&D to support new product launches and late-stage clinical programs like MariTide, while managing the regulatory and pricing challenges introduced by the IRA. The company’s focus remains on balancing capital allocation between R&D, debt repayment, and shareholder returns, despite a complex landscape of regulatory challenges, including the recent FDA proposal regarding TAVNEOS.
Key Takeaways for Amgen Inc
- FDA proposed withdrawal of TAVNEOS approval in April 2026 citing lack of efficacy evidence and safety issues, a major threat to a key rare disease asset.
- Settlement of major patent litigations for Repatha in March 2026 resolves longstanding disputes with Sanofi and Regeneron across multiple jurisdictions.
- Revenue growth of 5.8% YoY in Q1 2026 driven by 9% volume increase, partially offset by pricing and inventory headwinds.
- Significant patent expirations for Prolia and XGEVA in 2025 continue to drive accelerated sales erosion, with Prolia sales down 34% YoY in Q1 2026.
- Debt activity in Q1 2026 included $0.8 billion of repayments and $0.3 billion of notes repurchased (for $233 million), but about $4.0 billion of new debt was issued, lifting total debt to $57.3 billion from $54.6 billion at year-end 2025.
- MariTide continues to show promising Phase 2 data and advanced into global Phase 3 clinical trials, marking a critical strategic focus for future growth in the obesity/metabolic market.
What Does Amgen Inc Do?
Amgen discovers, develops, manufactures, and delivers human therapeutics targeting serious illnesses in areas of high unmet medical need. Its portfolio spans a range of modalities including large molecule biologics and small-molecule drugs. The company operates globally with a significant presence in approximately 100 countries, leveraging a robust manufacturing network and deep expertise in human genetics to drive innovation. Amgen serves a diverse range of customers including healthcare providers, physicians, clinics, hospitals, and pharmacies, primarily through wholesale distributors. The business model is differentiated by its end-to-end capabilities, from cutting-edge R&D centers to sophisticated large-scale biomanufacturing facilities. Amgen is a leader in the biotechnology industry, historically driving value through both internal innovation and strategic acquisitions to broaden its therapeutic offerings.